Charles Landen

Education

  • BS, University of North Carolina at Chapel Hill
  • MD, University of North Carolina at Chapel Hill
  • MS, University of Texas Health Sciences Center, Houston

Contact

  • Phone: 243-6131
  • Email: cl3nj

Research Interest(s)

Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies

Research Description

Selected Publications

  • Arend R. C., Londono-Joshi A. I., Samant R. S., Li Y., Conner M., Hidalgo B., Alvarez R. D., Landen C. N., Straughn J. M., Buchsbaum D. J.. Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol Oncol. 134(1): 112-20.
  • Chen H., Landen C. N., Li Y., Alvarez R. D., Tollefsbol T. O.. Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane J Oncol. 2013 872957.
  • Chen H., Landen C. N., Li Y., Alvarez R. D., Tollefsbol T. O.. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation Exp Cell Res. 319(5): 697-706.
  • Chien J., Kuang R., Landen C., Shridhar V.. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment Front Oncol. 3 251.
  • Cole M. E., Broaddus R., Thaker P., Landen C., Freedman R. S.. Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis Nat Clin Pract Oncol. 5(3): 171-5.
  • Dobbin Z. C., Katre A. A., Steg A. D., Erickson B. K., Shah M. M., Alvarez R. D., Conner M. G., Schneider D., Chen D., Landen C. N.. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer Oncotarget. 5(18): 8750-64.
  • Dobbin Z. C., Landen C. N.. Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications Curr Protoc Pharmacol. 63 Unit 14 28.
  • Dobbin Z. C., Landen C. N.. The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer Int J Mol Sci. 14(4): 8213-27.
  • Han L. Y., Fletcher M. S., Urbauer D. L., Mueller P., Landen C. N., Kamat A. A., Lin Y. G., Merritt W. M., Spannuth W. A., Deavers M. T., De Geest K., Gershenson D. M., Lutgendorf S. K., Ferrone S., Sood A. K.. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma Clin Cancer Res. 14(11): 3372-9.
  • Imai M., Landen C., Ohta R., Cheung N. K., Tomlinson S.. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer Cancer Res. 65(22): 10562-8.
  • Kim T. J., Landen C. N., Lin Y. G., Mangala L. S., Lu C., Nick A. M., Stone R. L., Merritt W. M., Armaiz-Pena G., Jennings N. B., Coleman R. L., Tice D. A., Sood A. K.. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer Cancer Biol Ther. 8(23): 2263-72.
  • Kim T. J., Ravoori M., Landen C. N., Kamat A. A., Han L. Y., Lu C., Lin Y. G., Merritt W. M., Jennings N., Spannuth W. A., Langley R., Gershenson D. M., Coleman R. L., Kundra V., Sood A. K.. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma Cancer Res. 67(19): 9337-45.
  • Landen C. N., Kim T. J., Lin Y. G., Merritt W. M., Kamat A. A., Han L. Y., Spannuth W. A., Nick A. M., Jennnings N. B., Kinch M. S., Tice D., Sood A. K.. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer Neoplasia. 10(11): 1259-67.
  • Landen C. N., Kinch M. S., Sood A. K.. EphA2 as a target for ovarian cancer therapy Expert Opin Ther Targets. 9(6): 1179-87.
  • Landen C. N., Klingelhutz A., Coffin J. E., Sorosky J. I., Sood A. K.. Genomic instability is associated with lack of telomerase activation in ovarian cancer Cancer Biol Ther. 3(12): 1250-3.
  • Landen C. N., Merritt W. M., Mangala L. S., Sanguino A. M., Bucana C., Lu C., Lin Y. G., Han L. Y., Kamat A. A., Schmandt R., Coleman R. L., Gershenson D. M., Lopez-Berestein G., Sood A. K.. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer Cancer Biol Ther. 5(12): 1708-13.
  • Lee J. W., Han H. D., Shahzad M. M., Kim S. W., Mangala L. S., Nick A. M., Lu C., Langley R. R., Schmandt R., Kim H. S., Mao S., Gooya J., Fazenbaker C., Jackson D., Tice D. A., Landen C. N., Coleman R. L., Sood A. K.. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma J Natl Cancer Inst. 101(17): 1193-205.
  • Li H., Cai Q., Wu H., Vathipadiekal V., Dobbin Z. C., Li T., Hua X., Landen C. N., Birrer M. J., Sanchez-Beato M., Zhang R.. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK Mol Cancer Res. 10(11): 1462-72.
  • Liles D., Landen C. N., Monroe D. M., Lindley C. M., Read M. S., Roberts H. R., Brinkhous K. M.. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B Thromb Haemost. 77(5): 944-8.
  • Lin Y. G., Han L. Y., Kamat A. A., Merritt W. M., Landen C. N., Deavers M. T., Fletcher M. S., Urbauer D. L., Kinch M. S., Sood A. K.. EphA2 overexpression is associated with angiogenesis in ovarian cancer Cancer. 109(2): 332-40.
  • Lu C., Kamat A. A., Lin Y. G., Merritt W. M., Landen C. N., Kim T. J., Spannuth W., Arumugam T., Han L. Y., Jennings N. B., Logsdon C., Jaffe R. B., Coleman R. L., Sood A. K.. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma Clin Cancer Res. 13(14): 4209-17.
  • Lu C., Shahzad M. M., Moreno-Smith M., Lin Y. G., Jennings N. B., Allen J. K., Landen C. N., Mangala L. S., Armaiz-Pena G. N., Schmandt R., Nick A. M., Stone R. L., Jaffe R. B., Coleman R. L., Sood A. K.. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models Cancer Biol Ther. 9(3): 176-82.
  • Lu C., Shahzad M. M., Wang H., Landen C. N., Kim S. W., Allen J., Nick A. M., Jennings N., Kinch M. S., Bar-Eli M., Sood A. K.. EphA2 overexpression promotes ovarian cancer growth Cancer Biol Ther. 7(7): 1098-103.
  • Lu C., Thaker P. H., Lin Y. G., Spannuth W., Landen C. N., Merritt W. M., Jennings N. B., Langley R. R., Gershenson D. M., Yancopoulos G. D., Ellis L. M., Jaffe R. B., Coleman R. L., Sood A. K.. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer Am J Obstet Gynecol. 198(4): 477 e1-9; discussion 477 e9-10.
  • Mathur S. P., Landen C. P., Datta S. M., Hoffman M. C., Mathur R. S., Young R. C.. Insulin-like growth factor II in gynecological cancers: a preliminary study Am J Reprod Immunol. 49(2): 113-9.
  • Merritt W. M., Kamat A. A., Hwang J. Y., Bottsford-Miller J., Lu C., Lin Y. G., Coffey D., Spannuth W. A., Nugent E., Han L. Y., Landen C. N., Nick A. M., Stone R. L., Coffman K., Bruckheimer E., Broaddus R. R., Gershenson D. M., Coleman R. L., Sood A. K.. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer Cancer Biol Ther. 10(12): 1306-14.
  • Merritt W. M., Lin Y. G., Spannuth W. A., Fletcher M. S., Kamat A. A., Han L. Y., Landen C. N., Jennings N., De Geest K., Langley R. R., Villares G., Sanguino A., Lutgendorf S. K., Lopez-Berestein G., Bar-Eli M. M., Sood A. K.. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth J Natl Cancer Inst. 100(5): 359-72.
  • Nick A. M., Stone R. L., Armaiz-Pena G., Ozpolat B., Tekedereli I., Graybill W. S., Landen C. N., Villares G., Vivas-Mejia P., Bottsford-Miller J., Kim H. S., Lee J. S., Kim S. M., Baggerly K. A., Ram P. T., Deavers M. T., Coleman R. L., Lopez-Berestein G., Sood A. K.. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death J Natl Cancer Inst. 103(21): 1596-612.
  • Qin Y., Xu J., Aysola K., Oprea G., Reddy A., Matthews R., Okoli J., Cantor A., Grizzle W. E., Partridge E. E., Reddy E. S., Landen C., Rao V. N.. BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9 Am J Cancer Res. 2(5): 540-8.
  • Schultz M. J., Swindall A. F., Wright J. W., Sztul E. S., Landen C. N., Bellis S. L.. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells J Ovarian Res. 6(1): 25.
  • Shah M. M., Dobbin Z. C., Nowsheen S., Wielgos M., Katre A. A., Alvarez R. D., Konstantinopoulos P. A., Yang E. S., Landen C. N.. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer Gynecol Oncol. 134(2): 331-7.
  • Shah M. M., Landen C. N.. Ovarian cancer stem cells: are they real and why are they important? Gynecol Oncol. 132(2): 483-9.
  • Shahzad M. M., Lu C., Lee J. W., Stone R. L., Mitra R., Mangala L. S., Lu Y., Baggerly K. A., Danes C. G., Nick A. M., Halder J., Kim H. S., Vivas-Mejia P., Landen C. N., Lopez-Berestein G., Coleman R. L., Sood A. K.. Dual targeting of EphA2 and FAK in ovarian carcinoma Cancer Biol Ther. 8(11): 1027-34.
  • Sood A. K., Bhatty R., Kamat A. A., Landen C. N., Han L., Thaker P. H., Li Y., Gershenson D. M., Lutgendorf S., Cole S. W.. Stress hormone-mediated invasion of ovarian cancer cells Clin Cancer Res. 12(2): 369-75.
  • Steg A. D., Bevis K. S., Katre A. A., Ziebarth A., Dobbin Z. C., Alvarez R. D., Zhang K., Conner M., Landen C. N.. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer Clin Cancer Res. 18(3): 869-81.
  • Steg A. D., Burke M. R., Amm H. M., Katre A. A., Dobbin Z. C., Jeong D. H., Landen C. N.. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer Oncotarget. 5(16): 7065-80.
  • Steg A. D., Katre A. A., Bevis K. S., Ziebarth A., Dobbin Z. C., Shah M. M., Alvarez R. D., Landen C. N.. Smoothened antagonists reverse taxane resistance in ovarian cancer Mol Cancer Ther. 11(7): 1587-97.
  • Steg A. D., Katre A. A., Goodman B., Han H. D., Nick A. M., Stone R. L., Coleman R. L., Alvarez R. D., Lopez-Berestein G., Sood A. K., Landen C. N.. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer Clin Cancer Res. 17(17): 5674-85.
  • Stone R. L., Nick A. M., McNeish I. A., Balkwill F., Han H. D., Bottsford-Miller J., Rupairmoole R., Armaiz-Pena G. N., Pecot C. V., Coward J., Deavers M. T., Vasquez H. G., Urbauer D., Landen C. N., Hu W., Gershenson H., Matsuo K., Shahzad M. M., King E. R., Tekedereli I., Ozpolat B., Ahn E. H., Bond V. K., Wang R., Drew A. F., Gushiken F., Lamkin D., Collins K., DeGeest K., Lutgendorf S. K., Chiu W., Lopez-Berestein G., Afshar-Kharghan V., Sood A. K.. Paraneoplastic thrombocytosis in ovarian cancer N Engl J Med. 366(7): 610-8.
  • Thaker P. H., Deavers M., Celestino J., Thornton A., Fletcher M. S., Landen C. N., Kinch M. S., Kiener P. A., Sood A. K.. EphA2 expression is associated with aggressive features in ovarian carcinoma Clin Cancer Res. 10(15): 5145-50.
  • Thaker P. H., Han L. Y., Kamat A. A., Arevalo J. M., Takahashi R., Lu C., Jennings N. B., Armaiz-Pena G., Bankson J. A., Ravoori M., Merritt W. M., Lin Y. G., Mangala L. S., Kim T. J., Coleman R. L., Landen C. N., Li Y., Felix E., Sanguino A. M., Newman R. A., Lloyd M., Gershenson D. M., Kundra V., Lopez-Berestein G., Lutgendorf S. K., Cole S. W., Sood A. K.. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med. 12(8): 939-44.
  • Vermillion S. T., Landen C. N.. Prostaglandin inhibitors as tocolytic agents Semin Perinatol. 25(4): 256-62.
  • Ziebarth A. J., Nowsheen S., Steg A. D., Shah M. M., Katre A. A., Dobbin Z. C., Han H. D., Lopez-Berestein G., Sood A. K., Conner M., Yang E. S., Landen C. N.. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer Clin Cancer Res. 19(1): 170-82.